Azithromycin versus tetracycline in the treatment of acne vulgaris

Journal of Dermatological Treatment

Volumn 17, Issue 4, 2006, Pages 217-221

  Rafiei, Rana ^a,b   Yaghoobi, Reza ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Emam Khomeini Hospital   (Iran)

Author keywords

Acne vulgaris; Azithromycin; Tetracycline; Treatment

Indexed keywords

AZITHROMYCIN; TETRACYCLINE;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; EPIGASTRIC PAIN; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARTBURN; HUMAN; INFLAMMATION; IRAN; MAJOR CLINICAL STUDY; MALE; OLIGOMENORRHEA; PRESCRIPTION; PRIORITY JOURNAL; PURPURA; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHOOL CHILD; SINGLE BLIND PROCEDURE; TINNITUS;

ACNE VULGARIS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; FEMALE; HUMANS; MALE; SINGLE-BLIND METHOD; TETRACYCLINE; TREATMENT OUTCOME;

EID: 33748704518     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630600866459     Document Type: Article

References (15)

1. Menadier J, Alirezai M. Systemic antibiotics for acne. Dermatology. 1998;196:135-9.
2. Madden WS, Ladells ID, Poulin Y, Searles GE, Smith KC, Tan JK, et al. Treatment of acne vulgaris: Canadian consensus guidelines. J Cutan Med Surg. 2000;4(suppl 1):S2-13.
3. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology. 2003;206:37-53.
4. Hughes BR, Murphy C, Barnett J, Cunliffe WJ. Strategy of acne therapy with long-term antibiotics. Br J Dermatol. 1989;121:623-8.
5. Eady EA, Gloor M, Leyden JJ. Propionibacterium acne resistance: A world wide problem. Dermatology. 2003;206:54-6.
6. Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int J Dermatol. 2000;39:45-50.
7. Ruggero C, Mauro B, Stefano V. Pulse therapy with azithromycin in acne: An open study. J Am Acad Dermatol. 2004;50:11(abstr).
8. Physicians' desk reference, 50th ed. Montval, NJ: Medical Economics Data Production Co.; 1996. p. 1944-6.
9. Heikkinen T, Laine K, Neuvoneon PJ, Ekblad U. The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. BJOG. 2000;107:770-5.
10. Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet. 1993;25:370-4.
11. Wallace RJ Jr, Griffin DE. Antimycobacterial agents. In: Kasper P, Braunwald E, Fauci A, eds. Harrison's principles of internal medicine, Vol 1. USA, New York: McGraw-Hill, 2005; chapter 149; page 946-953.
12. Foulds G, Hilligoss DM, Henry EB, Gerber N. The effects of an antacid or cimetidine on the serum concentrations of azithromycin. J Clin Pharmacol. 1991;31:164-7.
13. Elmer GW, Surawicz CM, Mcfarland LV. Biotherapeutic agents. A neglected modality for treatment and prevention of selected intestinal and vaginal infection. JAMA. 1996;275: 870-6.
14. Conly J, Stein K. Reduction of vitamin K2 concentration in human liver associated with the use of broad spectrum antimicrobials. Clin Invest Med. 1994;17:531-9.
15. Kelsey JJ, Moser LR, Jennings JC, Munger MA. Presence of azithromycin breast milk concentration: A case report. Am J Obstet Gynecol. 1994;170:1375-6.